World · Malaysia Bureau
Eli Lilly becomes first to secure China approval for GLP-1 weight-loss pill
The pharmaceutical giant has cleared a significant regulatory hurdle by obtaining Chinese market authorisation for an oral GLP-1 medication for weight management. The approval marks a shift in Beijing's approach to the drug class, which previously only permitted injectable formulations.
LSN Malaysia ·
Eli Lilly has achieved a milestone in China's pharmaceutical market by becoming the first drugmaker to win regulatory approval for an oral GLP-1 weight-loss medication, expanding treatment options beyond currently available injectable forms.
The approval represents a notable development in how Chinese authorities are approaching glucagon-like peptide-1 receptor agonists, a class of medications that have gained prominence globally for weight management applications. Until now, China's drug regulator had restricted GLP-1 approvals to injectable delivery methods only.
The move underscores growing international competition in the weight-management pharmaceutical sector, where GLP-1 medications have demonstrated significant clinical efficacy. Oral formulations offer patients greater convenience compared to injectable alternatives, potentially broadening the addressable market for such treatments.
Eli Lilly's approval in China positions the company to capitalise on the world's second-largest pharmaceutical market, where obesity and metabolic health concerns are increasingly drawing regulatory and clinical attention. The authorisation is expected to strengthen the company's competitive standing in the region's obesity treatment landscape.